Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral LBH589 in Refractory Cutaneous T-Cell Lymphoma
NCT00425555Phase 2Completed
- Sponsor
- Novartis
- Start
- Jan 2007
- Primary completion
- Jun 2013
- Modality
- Small Molecules
- Countries
- 12
01
Overview
A Phase 2 trial of panobinostat in cutaneous T-cell lymphoma (CTCL), sponsored by Novartis. Started Jan 2007; status: completed.
02
Drugs
panobinostat
03
Conditions
cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on NCT00425555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00425555.